Business
Nicox Provides Full Year 2025 Financial Results and Corporate Update
Press Release Nicox Provides Full Year 2025 Financial Results and Corporate Update Revenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024)NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone paymentRegulatory milestones anticipated to extend cash runway beyond 2027 April 30, 2026 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an
About this update from Nicox Sa
Income Statement Balance sheet 1 For illustrative purposes, if all the convertible bonds announced today were converted based on the Nicox share price at the close market on April 29, 2026 and of outstanding shares as of April 29, 2026, a shareholder holding 1.00% of Nicox's share capital prior to the transaction would see their holding reduced to 0.97% of the share capital on a non-diluted basis and to 0.74% on a fully diluted basis (taking into account existing dilutive instruments). Attachment